✨
AI Summary
- Discussed FDA leadership, including Heidi Overton's influence and Kyle Diamantis's role.
- Explored Eli Lilly's strategy against compounded GLP-1 drugs and the rise of retatrutide.
- Examined the competitive landscape between Hims & Hers and Ro, and the role of peptides.
Guests on This Episode
BS
Bijan Salehizadeh
1 podcast appearance